In last trading session, Sangamo Therapeutics Inc (NASDAQ:SGMO) saw 3.58 million shares changing hands with its beta currently measuring 1.47. Company’s recent per share price level of $1.12 trading at $0.02 or 1.82% at ring of the bell on the day assigns it a market valuation of $233.68M. That closing price of SGMO’s stock is at a discount of -183.93% from its 52-week high price of $3.18 and is indicating a premium of 73.21% from its 52-week low price of $0.30.
For Sangamo Therapeutics Inc (SGMO), analysts’ consensus is at an average recommendation of Hold while assigning it a mean rating of 1.71. Splitting up the data highlights that, out of 3 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 2 suggested the stock as a Hold whereas 1 see the stock as a Buy. 0 analyst(s) advised it as an Underweight. The company is expected to be making an EPS of 0 in the current quarter.
Sangamo Therapeutics Inc (NASDAQ:SGMO) trade information
Upright in the green during last session for gaining 1.82%, in the last five days SGMO remained trading in the red while hitting it’s week-highest on Tuesday, 02/18/25 when the stock touched $1.12 price level, adding 9.55% to its value on the day. Sangamo Therapeutics Inc’s shares saw a change of 9.80% in year-to-date performance and have moved -0.88% in past 5-day. Sangamo Therapeutics Inc (NASDAQ:SGMO) showed a performance of -0.88% in past 30-days.
Wall Street analysts have assigned a consensus price target of 2.5 to the stock, which implies a rise of 55.2% to its current value. Analysts have been projecting 2 as a low price target for the stock while placing it at a high target of 3. It follows that stock’s current price would drop -78.57% in reaching the projected high whereas dropping to the targeted low would mean a loss of -78.57% for stock’s current value.
Sangamo Therapeutics Inc (SGMO) estimates and forecasts
This year revenue growth is estimated to fall -64.54% from the last financial year’s standing.
7 industry analysts have given their estimates about the company’s current quarter revenue by setting an average figure of 11.7M for the same. And 3 analysts are in estimates of company making revenue of 30.67M in the next quarter. Company posted 2.04M and 481k of sales in current and next quarters respectively a year earlier.
Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of -15.96% during past 5 years. In 2025, company’s earnings growth rate is likely to be around 68.13% while estimates for its earnings growth in next 5 years are of 41.66%.
Sangamo Therapeutics Inc (NASDAQ:SGMO)’s Major holders
WASATCH ADVISORS LP is the top institutional holder at SGMO for having 20.09 million shares of worth $7.2 million. And as of 2024-06-30, it was holding 9.8509 of the company’s outstanding shares.
The second largest institutional holder is ARMISTICE CAPITAL, LLC, which was holding about 14.06 million shares on 2024-06-30. The number of shares represents firm’s hold over 6.894 of outstanding shares, having a total worth of $5.04 million.
On the other hand, Wasatch Ultra Growth Fund and Vanguard Total Stock Market Index Fund are the top two Mutual Funds which own company’s shares. As of Dec 31, 2024 , the former fund manager was holding 5.79 shares of worth $6.49 million or 2.78% of the total outstanding shares. The later fund manager was in possession of 5.65 shares on Sep 30, 2024 , making its stake of worth around $6.32 million in the company or a holder of 2.71% of company’s stock.
